atai Life Sciences (NASDAQ: ATAI) (atai), a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health disorders, has announced the pricing of a registered underwritten offering of 23,725,000 common shares, at a price of US$5.48 per share. atai has granted the underwriters a 30-day option to purchase up to an additional 3,558,750 common shares at the public offering price, less the underwriting discount. All common shares to be sold in the offering will be sold by atai. The offering is expected to close on October 20, 2025, subject to customary closing conditions.
Latham & Watkins represents atai Life Sciences in the offering with a corporate team led by partner Nathan Ajiashvili, with associates Kaj Nielsen, Adam Picker, and Elana Cates. Advice was also provided on public company representation matters by counsel Irina Yevmenenko, with associate Catriela Cohen.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
The advising firms, the named deal team, the value and the parties, with every other announced deal by the same firms and lawyers. Open the deal record
